Reading LTRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LTRN free→Reading LTRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LTRN free→QuarterlyIQ Insights · LTRN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Other Events. On May 13, 2026, the Company announced, by way of the press release attached hereto as Exhibit 99.1, the pricing of the offering described above and plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing AI technology assets into an independent business entity in order to access dedicated funding sources and pote…
Entry into a Material Definitive Agreement. On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $2.06 per share, and (ii) pre-funded warran…
Unregistered Sale of Equity Securities. The applicable information set forth in
Results of Operations and Financial Condition. On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities…
Results of Operations and Financial Condition. On November 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…
Results of Operations and Financial Condition. On August 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 24, 2025, the Board of Directors (“Board”) of Lantern Pharma Inc. (the “Company”), acting upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Lee T. Schalop, M.D. to the Board. In 2009, Dr. Schalop was a co-founder of Oncoceutics, Inc., a clinical-stage drug discovery and development company, and s…
Entry Into a Material Definitive Agreement . On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Agent”), pursuant to which the Company may offer and sell up to $15,530,000 maximum aggregate offering price of shares (the “Placement Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) from time to time through the Agent, acting as sales agent or pri…
Results of Operations and Financial Condition. On May 15, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On March 27, 2025, Lantern Pharma Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.